GB201017519D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB201017519D0
GB201017519D0 GBGB1017519.8A GB201017519A GB201017519D0 GB 201017519 D0 GB201017519 D0 GB 201017519D0 GB 201017519 A GB201017519 A GB 201017519A GB 201017519 D0 GB201017519 D0 GB 201017519D0
Authority
GB
United Kingdom
Prior art keywords
blebs
immunogens
strains
vaccines
hyperblebbing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1017519.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines Institue for Global Health SRL
Original Assignee
Novartis Vaccines Institute for Global Health SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines Institute for Global Health SRL filed Critical Novartis Vaccines Institute for Global Health SRL
Priority to GBGB1017519.8A priority Critical patent/GB201017519D0/en
Publication of GB201017519D0 publication Critical patent/GB201017519D0/en
Priority to PCT/IB2011/054569 priority patent/WO2012049662A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Hyperblebbing Salmonella strains are generated by disrupting one or more components of the Tol-Pal system, such as TolR. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.
GBGB1017519.8A 2010-10-15 2010-10-15 Vaccines Ceased GB201017519D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1017519.8A GB201017519D0 (en) 2010-10-15 2010-10-15 Vaccines
PCT/IB2011/054569 WO2012049662A1 (en) 2010-10-15 2011-10-14 Hyperblebbing salmonella strains

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1017519.8A GB201017519D0 (en) 2010-10-15 2010-10-15 Vaccines

Publications (1)

Publication Number Publication Date
GB201017519D0 true GB201017519D0 (en) 2010-12-01

Family

ID=43333951

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1017519.8A Ceased GB201017519D0 (en) 2010-10-15 2010-10-15 Vaccines

Country Status (2)

Country Link
GB (1) GB201017519D0 (en)
WO (1) WO2012049662A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
EP3310381B1 (en) * 2015-06-16 2023-06-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
EP4116316A1 (en) * 2015-07-04 2023-01-11 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
EP3749364A1 (en) 2018-02-09 2020-12-16 Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET) Immunomodulating and immunostimulating polypeptides for drug-delivery
EP3581201A1 (en) * 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
KR20210092224A (en) * 2018-11-10 2021-07-23 브하라트 바이오테크 인터내셔날 리미티드 Multivalent Glycoconjugate Immunogenic Composition
EP3808372A1 (en) * 2019-10-17 2021-04-21 GlaxoSmithKline Biologicals S.A. Novel vaccine compositions
GB202112149D0 (en) * 2021-08-24 2021-10-06 Glaxosmithkline Biologicals Sa Shigellla vaccine

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
HU219808B (en) 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Vaccine composition containing adjuvant and process for preparation thereof
DE69405551T3 (en) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A-CONTAINING VACCINE COMPOSITIONS
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE441432T1 (en) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst USE OF NON-METHYLATED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS ADJUVANTS
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100585408B1 (en) 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
AU2001264935A1 (en) 2000-05-24 2001-12-03 University Of Maryland Biotechnology Institute Method for introducing and expressing genes in animal cells, and bacterial blebsfor use in same
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
DK1742659T3 (en) 2004-04-05 2013-06-03 Zoetis P Llc Microfluidized oil-in-water emulsions and vaccine compositions
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs

Also Published As

Publication number Publication date
WO2012049662A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
GB0917002D0 (en) Improved shigella blebs
GB201017519D0 (en) Vaccines
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MX2016002571A (en) Transduction buffer.
EA201291157A1 (en) MULTIVALENT VACCINES WITH SYNTHETIC NANOSATORS
EA201300915A1 (en) NEW EUROPEAN PRRSV STRAIN
PH12016502220A1 (en) Means and methods for treating cmv
MX349630B (en) Alpha-amylases.
MX344972B (en) Immunostimulatory oligonucleotides.
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2020002544A (en) Glycopyrrolate salts.
MX2021014663A (en) Compound targeting il-23a and tnf-alpha and uses thereof.
PH12015501101A1 (en) Method for eliciting an immune response to an immunogen
MY191539A (en) Streptococcal vaccine
SG10201900041VA (en) Meningococcus vaccines
IN2014MU00455A (en)
MA37749B1 (en) Vaccines against bluetongue and African horse sickness virus
MX2013003859A (en) Picropodophyllin polymorphs b or c for use in cancer therapy.
MX367773B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof.
MX2018005134A (en) Fviii formulation.
MX2015012124A (en) Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing.
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRvIII SEQUENCE FOR THE TREATMENT OF TUMORS
IN2013CH05865A (en)

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)